intermediate risk neuroblastomas
Conditions
Interventions
Patients were given induction therapy LI-B (vincristine 1.5mg/m2 and cyclophosphamide 600mg/m2on day 1, pirarubicin 30mg/m2 on day 3) or LI-C (vincristine 1.5mg/m2, cyclophosphamide 900mg/m2 and carbo
Sponsors
Japan Neuroblastoma Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)age;day0-18 years old (2)diagnosis;histologically confirmed neuroblastoma or ganglioneuroblastoma by biopsy sample of primary tumor or metastatic tumor (include bone marrow). However, if the urine VMA and HVA (tumor marker) increase and MIBG scintigraphy are positivities, when the biopsy is difficult because of patient's condition, the patients can be diagnosed as the neuroblastoma. (3)staging and prognostic factors stage 3 (12months<= and Favorable Histology,12-18months and Unfavorable Histology) MYCN gene not amplification stage 4(12 months>, 12-18months and Favorable Histology and DNA index>1) MYCN gene not amplification stage 4S(Unfavorable Histology or Favorable Histology and DNA index=1) MYCN gene not amplification (4) no pre-emptive chemotherapy or radiotherapy (5) adequate major organ 1)Lansky performance status;30<= 2)Hemoatologic fanction;WBC>= 2000/mm3 3)Hepatic fanction;ALT 300 IU/l <= and t-bil 2.0 mg/dl>= 4)Renal fanction; 5 years old > 0.8 mg/dl>=, 5-10 years old 1.2 mg/dl>=, 10-18 years 1.5 mg/dl>=, 5)cardiac fanction; unnessesary treatment (6) written informed consent
Exclusion criteria
Exclusion criteria: (1)duplicate cancer (2)history of pregnancy or lactation (3) Patients complicated the mental disease or psychotic condition and were judged that can not participate in the study. (4) Patients whose participation in the study is judged to be inappropriate by the attending doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3 years progression-free survival rates | — |
Countries
Japan
Contacts
Public ContactTomoko Iehara
Kyoto Prefectural University of Medicine Pediatrics
Outcome results
None listed